Evotec SE: Strategic Realignment Focused on Core Competencies and Profitable Growth Until 2028!

Between 2023 and 2030, numerous patents for blockbuster drugs (e.g., in the oncology, autoimmune, and diabetes sectors) will expire. It is estimated that during this period, drugs valued at over $200 billion will be lost due to the expiration of patent protection. Pharmaceutical companies are under pressure to develop new active ingredients quickly and efficiently. This is where Evotec SE (i.) comes in with its scalable R&D infrastructure, especially in areas such as protein degradation, stem cell platforms, and RNA targeting. The company utilizes...